Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. American Hormones, Inc.
WARNING LETTER
•American Hormones, Inc.•December 29, 2006

American Hormones, Inc. – FDA Warning Letter, Dec 29, 2006

Record Details

An FDA inspection of American Hormones Inc. from December 14-29, 2006, revealed serious violations of the Federal Food, Drug, and Cosmetic Act (FDCA). The firm, purporting to be a compounding pharmacy, was found to operate more like a pharmaceutical manufacturer, mass-producing copies of FDA-approved drugs and products with active ingredients not found in approved drugs (e.g., Pregnenolone, DHEA, Estriol). These activities fall outside traditional pharmacy compounding.

The firm's products, including testosterone gel, thyroid capsules, pregnenolone capsules, DHEA capsules, and Estriol-containing hormone therapy products, are considered unapproved new drugs under FDCA Section 505(a) and misbranded under Section 502(f)(1) for lacking adequate directions for use. Furthermore, the drugs are adulterated under Section 501(a)(2)(B) due to numerous Current Good Manufacturing Practice (cGMP) violations (21 CFR Parts 210 and 211), including failures in stability testing, batch uniformity, equipment cleaning procedures, final product testing, process controls, component testing, and complaint handling. Additionally, hormone therapy products containing Estriol are misbranded under Section 502(a) due to unsubstantiated efficacy, superiority, and "bio-identical" claims on the firm's website. The firm also failed to register as a manufacturer and list its drug products, leading to further misbranding under Sections 502(o) and 510(j).

American Hormones Inc. must promptly correct all cited violations and provide a written response within fifteen working days detailing corrective actions and prevention measures. Failure to comply may result in legal action, including seizure and injunction. The FDA also warned against compounding human growth hormone for unapproved uses.

Company
American Hormones, Inc.
Inspection date
December 29, 2006
Product type
Drugs
Office
New York District Office
Person
  • Otto D. Vitillo
View Company Profile

ID · be2576e6-c05c-4563-9f7e-847b6fd0e4e4

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 U.S.C. 331(a)21 U.S.C. 321(p)21 U.S.C. 35521 U.S.C. 355(b)21 U.S.C. 355(j)21.U.S.C. 355(a)21 U.S.C. 352(f)(1)21 CFR 201.11521 U.S.C. 355(i)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore American Hormones, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.